Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis
Authors
Benjamin Li (ORCID: https://orcid.org/0000-0002-1783-7013)
Lynn McRoy
Adam Brufsky (ORCID: https://orcid.org/0000-0001-8080-7960)
Rachel M. Layman (ORCID: https://orcid.org/0000-0002-8663-0331)
Xianchen Liu (ORCID: https://orcid.org/0000-0002-4325-2545)
Institutions
The University of Texas MD Anderson Cancer Center (US)
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis
Benjamin Li, Lynn McRoy, Adam Brufsky, Rachel M. Layman et al.
Citations
3 citations
Journal
The Breast
Topics
Advanced Breast Cancer Therapies
Field-Weighted Citation Impact (FWCI)
4.56
article
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis
Benjamin Li, Lynn McRoy, Adam Brufsky, Rachel M. Layman, Xianchen Liu
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
The BreastVol. 81
Institutions
The University of Texas MD Anderson Cancer Center (US), Pfizer (United States) (US), University of Pittsburgh Medical Center (US)